mani
virus
implic
util
modul
ubiquitin
proteasom
system
up
enhanc
viral
multipl
andor
sustain
persist
infect
mosquitoborn
venezuelan
equin
enceph
viru
veev
belong
togavirida
famili
import
biodefens
pathogen
select
agent
current
approv
vaccin
therapi
veev
infect
therefor
imper
identifi
novel
target
therapeut
develop
hypothes
function
up
requir
effici
veev
multipl
shown
nontox
concentr
bortezomib
fdaapprov
inhibitor
proteasom
prove
potent
inhibitor
veev
multipl
human
astrocytoma
cell
line
bortezomib
inhibit
virul
trinidad
donkey
trd
strain
attenu
strain
veev
addit
studi
virul
strain
eastern
equin
enceph
viru
eeev
western
equin
enceph
viru
weev
demonstr
bortezomib
broad
spectrum
inhibitor
new
world
alphavirus
timeofaddit
assay
show
bortezomib
effect
inhibitor
viral
multipl
even
drug
introduc
mani
hour
post
exposur
viru
mass
spectrometri
analys
indic
veev
capsid
protein
ubiquitin
infect
cell
valid
confoc
microscopi
immunoprecipit
assay
subsequ
studi
reveal
capsid
ubiquitin
earli
stage
infect
affect
bortezomib
treatment
studi
aid
futur
investig
identifi
host
protein
potenti
broad
spectrum
therapeut
target
treat
alphaviru
infect
eukaryot
proteasom
cylindr
shape
proteas
complex
locat
cytoplasm
nucleu
compris
proteolyt
core
one
two
regulatori
subunit
protein
destin
degrad
tag
multipl
copi
small
amino
acid
protein
ubiquitin
make
target
protein
identifi
degrad
regulatori
compon
addit
ubiquitin
target
protein
catalyz
three
step
process
activ
enzym
conjug
enzym
ligas
unfold
polyubiquitintag
protein
fed
core
proteasom
cleav
smaller
peptid
proteasom
three
type
catalyt
activ
chymotrypt
tryptic
peptidylglutamyl
chymotrypt
activ
cleav
larg
hydrophob
residu
cleavag
basic
acid
residu
due
tryptic
peptidylglutamyl
activ
respect
proteasom
inhibitor
use
studi
bortezomib
dipeptidyl
boron
acid
function
specif
revers
inhibit
proteasom
bortezomib
us
food
drug
administr
fda
approv
therapeut
proteasom
inhibitor
commerci
avail
velcad
use
treat
multipl
myeloma
mantl
cell
lymphoma
mechan
inhibit
ascrib
bortezomib
abl
form
tetrahedr
adduct
activ
threonin
site
within
proteolyt
core
thu
make
drug
attract
candid
drug
develop
tradit
function
proteasom
dispos
misfold
protein
gener
recycl
role
cell
recent
ubiquitin
proteasom
system
up
also
describ
play
role
nondegrad
process
cell
surviv
mhc
class
antigen
present
apoptosi
cell
divis
activ
dna
repair
transcript
regul
signal
transduct
endocytosi
intracellular
traffick
chemoresist
sever
virus
up
shown
antivir
activ
exampl
up
inhibit
entri
post
entri
step
influenza
viru
mous
hepat
viru
replic
express
human
coxsacki
viru
adenoviru
cytomegaloviru
infecti
bursal
diseas
viru
vesicular
stomat
viru
also
inhibit
up
contrast
mani
virus
implic
util
modul
up
establish
product
infecti
cycl
proteasom
inhibitor
act
deplet
free
ubiquitin
need
modifi
viral
protein
effici
viral
bud
inhibit
up
mani
effect
viral
replic
exampl
gag
polyprotein
process
hiv
infect
cell
affect
up
inhibit
thu
decreas
releas
infect
new
virion
case
herp
simplex
viru
hsv
ubiquitin
requir
releas
viral
dna
cytoplasm
dna
sensor
recogn
viral
dna
induc
interferon
respons
recent
studi
inhibit
host
up
inhibit
numer
aspect
life
cycl
differ
coronavirus
viral
entri
rna
synthesi
protein
express
venezuelan
equin
enceph
viru
veev
new
world
alphaviru
belong
togavirida
famili
veev
endem
south
america
extend
southern
region
unit
state
veev
mosquitoborn
viru
transmit
human
bite
infect
mosquito
also
via
aerosol
rout
determin
occurr
laboratoryacquir
infect
veev
easili
weapon
exhibit
past
therefor
consid
import
biodefens
pathogen
select
agent
human
infect
veev
display
symptom
rang
fever
headach
sore
throat
malais
myalgia
vomit
sever
neurolog
diseas
coma
current
fdaapprov
vaccin
therapeut
public
use
howev
liveattenu
strain
use
vaccin
militari
atrisk
personnel
inactiv
trival
encephalit
viru
commonli
use
hors
veev
envelop
viru
contain
singlestrand
posit
sens
rna
genom
nucleotid
encod
four
nonstructur
protein
five
structur
protein
capsid
envelop
glycoprotein
involv
synthesi
cap
viral
rna
newli
translat
polyprotein
cleav
viral
proteas
function
rna
polymeras
role
yet
fulli
character
howev
implic
rna
synthesi
role
pathogen
mice
interact
host
inhibitor
compon
ikk
complex
structur
protein
function
packag
bud
virion
particl
infect
cell
capsid
protein
origin
believ
select
packag
viral
genom
abl
cleav
polypeptid
capsid
protein
unravel
multifunct
viral
protein
cytoplasm
nuclear
distribut
infect
cell
due
nuclear
local
signal
sequenc
capsid
function
host
transcript
shutoff
result
cytopathogen
bind
ribosom
inhibit
nuclear
cytoplasm
traffick
host
protein
current
studi
hypothes
host
proteasom
system
requir
effici
veev
replic
shown
nontox
concentr
bortezomib
potent
inhibitor
veev
replic
astrocyt
cell
line
bortezomib
exhibit
broad
spectrum
inhibitori
potenti
interf
multipl
virul
strain
veev
eeev
weev
mass
spectrometri
analysi
indic
capsid
protein
ubiquitin
infect
cell
independ
valid
microscopi
immunoprecipit
assay
subsequ
studi
suggest
capsid
ubiquitin
earli
stage
infect
partli
inhibit
bortezomib
studi
provid
evid
import
role
play
host
proteasom
new
world
alphaviru
multipl
henc
identifi
host
proteasom
viabl
candid
develop
therapeut
virul
iab
trinidad
donkey
strain
trd
underw
initi
passag
chick
embryo
passag
guinea
pig
heart
cell
yield
passag
chick
fibroblast
cultur
plaqu
pick
fetal
guinea
pig
heart
cell
twice
yield
one
plaqu
select
passag
fetal
guinea
pig
heart
cell
use
product
lot
vaccin
obtain
bei
resourc
trd
genom
differ
nucleotid
posit
chang
noncod
region
envelop
glycoprotein
provid
attenu
replic
thoroughli
studi
vitro
vivo
serv
biosafeti
model
fulli
virul
veev
trd
strain
experi
perform
set
experi
virul
veev
trd
conduct
condit
virul
strain
eastern
equin
enceph
viru
eeev
obtain
dr
jonathan
jacob
mriglob
virul
western
equin
enceph
viru
weev
california
strain
obtain
atcc
select
agent
use
regist
center
diseas
control
prevent
experi
conduct
georg
mason
univers
biomed
research
laboratori
regist
accord
feder
select
agent
regul
human
astrocytoma
cell
cell
african
green
monkey
kidney
epitheli
cell
vero
cell
maintain
dmem
supplement
fetal
bovin
serum
penicillinstreptomycin
lglutamin
co
cell
seed
cell
per
well
plate
follow
day
pretreat
inhibitor
bortezomib
santa
cruz
biotechnolog
santa
cruz
biotechnolog
hour
medium
contain
inhibitor
henceforth
refer
condit
medium
cell
infect
hour
allow
viral
adsorpt
viral
inoculum
remov
replac
condit
media
cell
incub
co
supernat
collect
hour
later
store
analyz
vero
cell
seed
plate
densiti
cell
per
well
viral
supernat
tenfold
serial
dilut
dmem
use
infect
vero
cell
duplic
plate
incub
hour
co
occasion
rock
overlay
compris
emem
agaros
ad
well
solidifi
plate
incub
addit
hour
co
formaldehyd
solut
ad
surfac
agaros
plug
incub
hour
room
temperatur
plate
rins
dih
agaros
plug
remov
crystal
violet
solut
contain
ethanol
ad
well
incub
minut
room
temperatur
whilst
rock
plate
rins
visibl
plaqu
count
viral
titer
determin
pfuml
cell
viabil
measur
use
celltiterglo
luminesc
cell
viabil
kit
promega
follow
manufactur
instruct
briefli
cell
seed
white
wall
plate
cell
per
well
next
day
cell
treat
vari
concentr
bortezomib
incub
addit
hour
cell
viabil
determin
celltiterglo
assay
wherebi
reagent
ad
cell
ratio
plate
shaken
minut
incub
minut
room
temperatur
luminesc
detect
use
dtx
multimod
detector
beckman
coulter
cell
seed
plate
densiti
cell
per
well
incub
hour
condit
media
remov
cell
infect
hour
condit
media
replac
infect
cell
treat
bortezomib
vari
hour
post
infect
control
infect
cell
treat
dmso
supernat
collect
hour
post
infect
store
readi
perform
plaqu
assay
ubiquitin
plasmid
ha
tag
haub
kind
gift
dr
benhur
lee
david
geffen
school
medicin
univers
california
lo
angel
transfect
perform
use
attracten
transfect
reagent
qiagen
per
manufactur
instruct
control
plasmid
use
transfect
perform
hour
optim
protein
express
prepar
whole
cell
lysat
previous
describ
cell
infect
moi
maintain
co
hour
post
infect
cell
collect
lyse
buffer
contain
trishcl
ph
nacl
mm
edta
mm
naf
mm
mm
dtt
mm
one
tablet
complet
proteas
inhibitor
cocktail
per
ml
cell
lysi
perform
ice
minut
lysat
centrifug
minut
rpm
supernat
transfer
new
tube
protein
quantit
bradford
protein
assay
biorad
hercul
ca
usa
two
milligram
total
protein
incub
overnight
rotat
veev
capsid
antibodi
bei
resourc
nr
isotyp
igg
control
antibodi
slurri
protein
ag
bead
calbiochem
rockland
ad
immunoprecipit
ip
incub
hour
rotat
ip
centrifug
briefli
bead
wash
whole
cell
lysat
separ
trisglycin
gel
transfer
polyvinyl
difluorid
pvdf
membran
use
iblot
gel
transfer
system
invitrogen
primari
antibodi
veev
capsid
ubiquitin
abcam
antiubiquitin
linkagespecif
antibodi
abcam
use
accord
manufactur
instruct
blot
incub
respect
secondari
hrpcoupl
antibodi
membran
visual
chemiluminesc
use
supersign
west
femto
maximum
sensit
substrat
kit
thermoscientif
biorad
molecular
imag
chemidoc
xr
system
biorad
cell
either
transfect
haub
hour
transfect
cell
infect
moi
infect
cell
maintain
co
hour
post
infect
cell
collect
lyse
process
describ
two
milligram
total
protein
quantifi
bradford
assay
incub
overnight
rotat
normal
mous
igg
antibodi
santa
cruz
biotechnolog
antibodi
santa
cruz
biotechnolog
slurri
protein
ag
bead
calbiochem
rockland
ad
ip
incub
hour
rotat
ip
centrifug
briefli
bead
wash
twice
follow
singl
wash
lcmsm
analysi
carri
previous
describ
briefli
sampl
first
lyse
urea
reduc
use
dtt
acetyl
use
iodoacetamid
reduc
alkyl
protein
trypsin
digest
trypsin
promega
hour
digest
peptid
elut
use
ziptip
purif
millipor
analysi
peptid
perform
ltqtandem
msm
equip
reversephas
liquid
chromatographi
nanospray
thermofish
sampl
inject
column
wash
minut
nlmin
formic
acid
peptid
elut
use
linear
gradient
acetonitril
addit
step
acetonitril
formic
acid
minut
ltqm
oper
datadepend
mode
full
ms
scan
follow
five
msm
scan
five
abund
molecular
ion
dynam
select
fragment
collisioninduc
dissoci
use
normal
collis
energi
tandem
mass
spectra
match
nation
center
biotechnolog
inform
human
databas
sequest
biowork
softwar
thermofish
use
full
tryptic
cleavag
constraint
static
cystein
alkyl
iodoacetamid
veev
genom
sequenc
obtain
genbank
first
base
genom
use
design
rna
fish
probe
use
stellari
rna
fish
probe
design
version
biosearch
technolog
probe
set
individu
probe
gener
probe
tag
quasar
fluorophor
order
detect
viral
rna
cell
seed
onto
coverslip
plate
densiti
cell
per
well
cell
pretreat
bortezomib
dmso
hour
condit
media
remov
treat
cell
infect
moi
hour
incub
viral
inoculum
replac
condit
media
hour
post
infect
cell
fix
formaldehyd
minut
wash
place
ethanol
overnight
sampl
process
rna
fish
use
stellari
viral
rna
probe
accord
manufactur
protocol
hybrid
step
viral
rna
probe
dilut
concentr
nm
formamid
hybrid
buffer
probe
solut
ad
center
coverslip
follow
rna
hybrid
step
cell
wash
pb
solut
contain
dapi
dapi
solut
wash
cell
replac
pb
coverslip
mount
onto
slide
use
vectashield
hardmount
mount
medium
sampl
imag
use
zeiss
confoc
microscop
imag
obtain
use
object
vero
cell
infect
rvfv
strain
moi
hour
follow
infect
cell
process
rna
fish
describ
cell
stain
antinucleocapsid
antibodi
immunofluoresc
cell
seed
densiti
cell
per
well
chamber
slide
cell
either
bortezomib
treat
dmso
treat
uninfect
mock
infect
describ
cell
fix
paraformaldehyd
permeabil
triton
pb
follow
block
bsa
triton
pb
minut
slide
incub
primari
antibodi
hour
dark
room
temperatur
slide
wash
three
time
pb
incub
respect
secondari
antibodi
alexa
fluor
antibodi
invitrogen
hour
dark
room
temperatur
slide
wash
three
time
pb
incub
dapi
minut
dark
room
temperatur
follow
addit
pb
wash
slide
mount
fluoromount
g
southernbiotech
store
dark
overnight
cell
imag
use
nikon
eclips
imag
taken
object
coloc
confirm
zstack
taken
increment
cell
pretreat
bortezomib
dmso
hour
infect
moi
hour
post
infect
cell
lyse
use
total
rna
isol
kit
life
technolog
per
manufactur
instruct
addit
control
cell
either
pretreat
bortezomib
dmso
hour
infect
moi
cell
lyse
hour
post
infect
viral
rna
quantit
use
qrtpcr
primer
probe
nucleotid
veev
qrtpcr
cycl
condit
follow
cycl
minut
cycl
minut
cycl
second
minut
use
stepon
plu
real
time
pcr
system
primer
probe
pair
use
origin
describ
juland
forward
primer
tctgacaagacgttcccaatca
revers
primer
gaataacttccctccgaccaca
taqman
probe
n
n
n
qrtpcr
assay
perform
use
biorad
itaq
univers
probe
onestep
mix
biorad
absolut
quantif
calcul
base
threshold
cycl
ct
rel
standard
curv
pool
supernat
veev
infect
vero
cell
collect
hour
post
infect
centrifug
rpm
minut
five
percent
polyethylen
glycol
sodium
chlorid
ad
supernat
allow
stir
overnight
stir
supernat
centrifug
rpm
minut
supernat
discard
pellet
resuspend
pb
viru
suspens
layer
top
freshli
prepar
continu
sucros
densiti
gradient
gradient
centrifug
rpm
overnight
three
millimet
fraction
taken
top
resuspend
buffer
compris
tri
ph
mgcl
sucros
fraction
titer
plaqu
assay
determin
fraction
highest
puriti
infect
downstream
immunoprecipit
assay
individu
experi
perform
triplic
rna
fish
experi
perform
independ
experi
duplic
unless
otherwis
state
graph
averag
independ
experi
experiment
result
express
arithmet
mean
standard
deviat
calcul
independ
experi
repres
thusli
statist
analys
perform
unpair
twotail
student
ttest
use
graphpadsquickcalc
softwar
graphpad
up
pathway
great
import
regul
cellular
process
therefor
mani
virus
take
advantag
system
order
enhanc
viral
replic
determin
fda
approv
drug
bortezomib
proteasom
inhibitor
inhibit
multipl
cell
pretreat
bortezomib
hour
treat
cell
infect
hour
condit
media
replac
supernat
collect
hour
post
infect
store
analyz
plaqu
assay
cell
treat
dmso
serv
control
fig
illustr
presenc
bortezomib
multipl
decreas
dosedepend
fashion
compar
dmso
control
bortezomib
decreas
multipl
log
log
bortezomib
decreas
observ
fig
ensur
inhibit
due
toxic
drug
cell
pretreat
dmso
concentr
bortezomib
fig
bortezomib
inhibit
multipl
cell
cell
seed
plate
densiti
cell
per
well
cell
either
pretreat
dmso
bortezomib
triplic
hour
condit
media
remov
prior
infect
moi
hour
viral
inoculum
remov
replac
condit
media
supernat
collect
hour
post
infect
store
analyz
plaqu
assay
determin
infecti
viral
titer
pfuml
b
cell
seed
white
wall
plate
densiti
cell
per
well
cell
either
pretreat
dmso
bortezomib
triplic
hour
cell
viabil
measur
use
celltiterglo
luminesc
cell
viabil
kit
wherebi
reagent
ad
cell
ratio
plate
shaken
minut
incub
minut
room
temperatur
luminesc
detect
use
dtx
multimod
detector
beckman
coulter
arithmet
mean
illustr
graphic
graph
repres
independ
experi
perform
triplic
standard
deviat
calcul
independ
experi
p
infecti
viral
titer
fig
left
panel
demonstr
bortezomib
inhibit
multipl
moi
test
compar
dmso
control
western
blot
analysi
infect
lysat
illustr
increas
viral
structur
protein
express
capsid
glycoprotein
increas
viral
load
presenc
bortezomib
howev
decreas
viral
structur
protein
observ
compar
dmso
control
fig
right
panel
observ
decreas
capsid
glycoprotein
express
affect
increas
moi
taken
togeth
result
indic
nontox
concentr
bortezomib
inhibit
multipl
independ
initi
viral
load
initi
experi
evalu
efficaci
bortezomib
inhibit
multipl
involv
pretreat
cell
inhibitor
determin
whether
bortezomib
could
function
effect
inhibitor
viral
multipl
introduc
post
infecti
exposur
time
addit
assay
perform
object
experi
determin
time
post
exposur
bortezomib
treatment
still
efficaci
inhibit
viru
schemat
assay
repres
fig
briefli
cell
infect
moi
b
moi
c
moi
hour
bortezomib
ad
infect
cell
hour
interv
hour
post
infect
infect
cell
treat
dmso
serv
control
supernat
collect
hour
post
infect
analyz
plaqu
assay
infecti
viral
particl
fig
signific
decreas
multipl
observ
bortezomib
treat
cell
time
point
investig
compar
dmso
control
despit
increas
viral
load
observ
indic
bortezomib
success
appli
inhibit
viral
multipl
ad
hour
post
infect
next
hypothes
drug
provid
post
exposur
longer
drug
avail
greater
would
extent
inhibit
also
support
wellknown
notion
bortezomib
mediat
inhibit
revers
bortezomib
remov
system
viral
multipl
would
resum
schemat
modifi
time
addit
assay
repres
fig
cell
subject
hour
pretreat
bortezomib
follow
infect
moi
f
moi
g
moi
h
hour
adsorpt
condit
media
ad
back
infect
cell
time
point
indic
condit
media
replac
cultur
media
supernat
collect
hour
post
infect
analyz
plaqu
assay
fig
indic
earlier
time
point
bortezomib
remov
multipl
resum
wherea
later
time
point
bortezomib
remov
decreas
viral
titer
observ
furthermor
observ
decreas
influenc
increas
viral
titer
data
suggest
greater
inhibit
multipl
prolong
bortezomib
treatment
verifi
effect
bortezomib
multipl
mediat
impair
up
test
anoth
proteasom
inhibitor
peptid
aldehyd
inhibit
proteasom
activ
bind
activ
site
beta
subunit
henc
block
proteolyt
activ
proteasom
determin
reduc
viral
titer
similar
reduct
observ
bortezomib
cell
pretreat
hour
condit
medium
remov
cell
infect
hour
condit
media
replac
supernat
collect
hour
post
infect
plaqu
assay
perform
determin
viral
titer
depict
fig
shown
fig
decreas
viral
titer
observ
respect
compar
dmso
control
ensur
inhibit
due
toxic
drug
cell
viabil
determin
celltiterglo
assay
found
toxic
cell
concentr
test
fig
timeofaddit
assay
ident
fig
perform
fig
indic
also
capabl
inhibit
multipl
provid
post
exposur
manner
taken
togeth
result
suggest
inhibit
multipl
dosedepend
manner
observ
result
thu
far
led
us
hypothes
mechan
bortezomib
may
inhibit
viral
multipl
may
involv
impair
earli
event
includ
viral
capsid
stabil
may
interfer
releas
viral
genom
materi
enabl
subsequ
rna
replic
viral
protein
synthesi
plaqu
assay
perform
use
dmsotreat
bortezomibtr
cell
reveal
less
infecti
viru
present
supernat
drugtreat
cell
fig
address
hypothesi
bortezomib
treatment
may
interfer
extent
viral
rna
replic
quantifi
amount
intracellular
viral
rna
earli
stage
infecti
process
cytoplasm
drugtreat
cell
qrtpcr
use
veev
specif
primer
pretreat
infect
cell
lyse
variou
time
point
post
infect
analysi
intracellular
viral
rna
fig
illustr
decreas
veev
genom
copi
bortezomib
treat
cell
compar
correspond
dmso
control
addit
util
rna
fish
probe
design
specif
detect
intracellular
veev
genom
rna
order
determin
chang
intracellular
distribut
pattern
rna
presenc
bortezomib
fig
fish
analysi
illustr
hour
post
infect
bortezomib
treatment
inhibit
viral
rna
product
compar
control
follow
fish
stain
cell
imag
use
object
least
highpow
field
hpf
obtain
sampl
percentag
infect
uninfect
cell
calcul
per
hpf
condit
approxim
decreas
viral
rna
product
determin
fluoresc
signal
observ
bortezomib
treatment
hour
post
infect
progress
increas
intracellular
viral
rna
dmsotreat
cell
observ
ultim
reorgan
tight
cytoplasm
punctat
focilik
region
later
time
point
veevspecif
fish
probe
detect
viral
rna
hour
post
infect
fig
robust
rna
replic
reorgan
less
frequent
bortezomibtr
cell
support
possibl
observ
decreas
extracellular
infecti
virion
may
attribut
potenti
decreas
intracellular
viral
replic
rna
organ
relev
cytoplasm
structur
ensur
specif
veev
rna
fish
probe
util
rift
valley
fever
viru
strain
twenti
four
hour
post
infect
vero
cell
fix
process
rna
fish
stain
veev
vrna
specif
fish
probe
red
fig
subsequ
fish
stain
infect
cell
immunostain
detect
level
infect
observ
coloc
veev
capsid
viral
rna
infect
cell
thu
veev
rna
fish
probe
specif
veev
interact
rna
summari
data
reveal
bortezomib
treatment
result
decreas
intracellular
viral
rna
level
alter
rna
distribut
infect
cell
data
thu
far
support
idea
bortezomibtr
cell
veev
replic
decreas
earli
time
point
post
infect
henc
hypothes
observ
reduct
due
inhibit
viral
protein
capsid
would
normal
post
translat
modifi
ubiquitin
ultim
effect
intracellular
viral
rna
level
directli
indirectli
address
hypothesi
cell
transfect
haub
hour
infect
cell
lysat
prepar
hour
post
infect
haub
express
valid
western
blot
data
shown
total
cell
lysat
immunoprecipit
ha
antibodi
lcmsm
perform
control
ip
includ
isotyp
igg
antibodi
lcmsm
result
analyz
tabul
fig
mass
spectrometri
analysi
indic
viral
capsid
associ
ha
tag
ubiquitin
infect
cell
fig
indepth
investig
ubiquitin
statu
host
addit
viral
protein
entir
time
cours
alphaviru
infect
impact
viral
multipl
ongo
lab
confoc
microscopi
perform
independ
valid
capsid
ubiquitin
use
specif
antibodi
detect
capsid
ubiquitin
cell
infect
hour
post
infect
cell
fix
time
point
select
bortezomib
effect
inhibit
multipl
earli
hour
post
infect
fig
total
cell
count
cell
infect
coloc
shown
arrow
fig
capsid
ubiquitin
observ
infect
cell
translat
infect
cell
display
coloc
panel
eh
fig
serv
exampl
infect
cell
given
field
view
panel
zstack
imag
panel
eh
coloc
capsid
ubiquitin
shown
arrow
coloc
confirm
zstack
analysi
quantifi
tabul
cell
lysat
incub
capsid
antibodi
isotyp
igg
control
antibodi
cell
extract
resolv
sdspage
subsequ
immunoblot
probe
ubiquitin
capsid
fig
hour
post
infect
monoubiquitin
polyubiquitin
capsid
speci
observ
taken
togeth
result
indic
veev
capsid
ubiquitin
infect
cell
collect
result
thu
far
suggest
capsid
ubiquitin
earli
stage
infect
support
requir
function
proteasom
system
may
permit
degrad
capsid
releas
viral
genom
rna
cytoplasm
infect
cell
potenti
host
proteinsfactor
ubiquitin
prevent
degrad
alphaviru
infect
manuscript
howev
focus
capsid
protein
ubiquitin
infect
host
cell
ubiquitin
known
target
protein
proteasom
degrad
therefor
determin
whether
capsid
ubiquitin
linkag
infecti
process
perform
studi
use
antibodi
specif
detect
ubiquitin
infect
cell
use
confoc
microscopi
cell
infect
hour
post
infect
cell
fix
probe
ubiquitin
capsid
coloc
capsid
ubiquitin
observ
alltim
point
investig
shown
arrow
fig
panel
ex
fig
serv
exampl
infect
cell
given
field
view
panel
n
zstack
imag
panel
h
respect
panel
x
zoom
zstack
imag
panel
r
w
respect
referenc
red
box
coloc
capsid
ubiquitin
shown
arrow
fig
coloc
confirm
zstack
analysi
quantifi
tabul
fig
earli
hour
post
infect
coloc
capsid
ubiquitin
observ
hour
post
infect
coloc
record
respect
confoc
microscopi
bortezomib
decreas
intracellular
viral
rna
cell
seed
plate
densiti
cell
per
well
cell
pretreat
bortezomib
dmso
hour
infect
moi
hour
hour
post
infect
cell
lyse
total
rna
isol
kit
control
cell
either
pretreat
bortezomib
dmso
hour
infect
moi
cell
lyse
hour
post
infect
level
viral
rna
quantifi
qrtpcr
use
veev
specif
primer
cycl
condit
probe
primer
pair
sequenc
describ
method
section
graph
repres
averag
independ
experi
experi
perform
triplic
standard
deviat
calcul
accordingli
cell
seed
onto
coverslip
plate
densiti
cell
per
well
cell
pretreat
bortezomib
hour
infect
moi
b
c
b
hour
infect
cell
fix
process
rna
fish
describ
materi
method
section
follow
fish
stain
cell
imag
use
zeiss
confoc
microscop
object
least
highpow
field
hpf
obtain
sampl
percentag
infect
uninfect
cell
calcul
per
hpf
condit
repres
object
imag
shown
viral
rna
red
nuclei
blue
c
hour
infect
cell
fix
process
rna
fish
describ
materi
method
section
follow
fish
stain
cell
imag
use
zeiss
confoc
microscop
repres
object
imag
shown
viral
rna
red
nuclei
blue
vero
cell
infect
rift
valley
fever
viru
rvfv
strain
hour
cell
process
rna
fish
stain
veev
vrna
specif
fish
probe
describ
materi
method
section
follow
rna
fish
stain
veev
infect
cell
immunostain
antiveev
capsid
antibodi
rvfv
infect
cell
immunostain
antirvfv
nucleocapsid
antibodi
nuclei
detect
use
dapi
imag
shown
condens
zstack
imag
repres
independ
experi
perform
duplic
ubiquitin
reveal
clearli
discern
signal
capsid
protein
data
shown
data
indic
cours
infect
ubiquitin
capsid
decreas
sinc
proteasom
inhibitor
act
deplet
free
ubiquitin
hypothes
bortezomib
pretreat
decreas
avail
pool
free
ubiquitin
system
result
decreas
ubiquitin
capsid
compar
untreat
cell
address
confoc
microscopi
wherebi
cell
pretreat
dmso
bortezomib
untreat
mock
either
infect
uninfect
fig
ubiquitin
also
observ
bortezomib
treat
infect
cell
panel
il
panel
el
fig
serv
exampl
infect
cell
given
field
view
coloc
confirm
zstack
analysi
quantifi
tabul
fig
sinc
ubiquitin
confoc
microscopi
assay
distinguish
monoubiquitin
polyubiquitin
speci
capsid
coimmunoprecipit
perform
cell
pretreat
bortezomib
dmso
infect
cell
collect
hour
post
infect
lyse
quantifi
equal
amount
total
protein
immunoprecipit
capsid
isotyp
igg
control
subsequ
immunoblot
probe
ubiquitin
fig
observ
decreas
band
intens
monoubiquitin
polyubiquitin
capsid
bortezomib
treatment
densitometr
count
repres
graphic
illustr
decreas
monoubiquitin
decreas
polyubiquitin
bortezomib
treatment
compar
dmso
control
thu
far
result
indic
earli
time
point
infect
capsid
ubiquitin
affect
bortezomib
treatment
shown
bortezomib
inhibit
earli
stage
infect
fig
support
probabl
mechan
bortezomib
may
inhibit
ubiquitin
mediat
degrad
capsid
allow
releas
viral
genom
rna
cytoplasm
infect
cell
contribut
idea
incom
virion
ubiquitin
capsid
protein
henc
relev
popul
analyz
would
virion
attempt
determin
whether
capsid
protein
virion
ubiquitin
address
perform
triplic
sucros
densiti
centrifug
virusenrich
supernat
obtain
infect
vero
cell
six
fraction
analyz
plaqu
assay
determin
fraction
purest
viral
suspens
fig
fraction
depict
highest
titer
sucros
purifi
viru
pfuml
chosen
immunoprecipit
capsid
antibodi
isotyp
igg
antibodi
control
subsequ
blot
probe
ubiquitin
capsid
shown
fig
observ
valid
independ
duplic
hour
post
infect
cell
lysat
collect
quantifi
protein
concentr
two
milligram
total
protein
immunoprecipit
ha
probe
antibodi
mous
igg
control
lcmsm
perform
result
tabul
b
cell
seed
chamber
slide
cell
per
well
cell
uninfect
mock
infect
moi
hour
post
transfect
cell
fix
process
describ
materi
method
section
cell
probe
ubiquitin
capsid
antibodi
follow
incub
alexafluor
alexafluor
respect
cell
stain
dapi
observ
nuclei
imag
taken
use
nikon
eclips
object
repres
independ
experi
perform
duplic
c
cell
infect
moi
hour
hour
post
infect
cell
lysat
collect
quantifi
protein
concentr
two
milligram
total
protein
immunoprecipit
ubiquitin
antibodi
isotyp
igg
control
immunoprecipit
sampl
resolv
sdspage
subsequ
immunoblot
capsid
top
panel
ubiquitin
bottom
panel
imag
repres
independ
experi
immunoprecipit
run
monoubiquitin
polyubiquitin
form
capsid
observ
ad
evid
idea
capsid
protein
exist
ubiquin
form
veev
virion
veev
emerg
infecti
viru
caus
natur
outbreak
mani
part
world
veev
weapon
past
continu
classifi
biothreat
agent
owe
retent
stabil
infect
aerosol
form
divers
role
fig
veev
capsid
protein
ubiquitin
cell
seed
chamber
slide
cell
per
well
cell
uninfect
mock
infect
moi
hour
post
infect
cell
fix
process
describ
materi
method
section
cell
probe
ubiquitin
capsid
antibodi
follow
incub
alexafluor
alexafluor
respect
cell
stain
dapi
observ
nuclei
imag
taken
use
nikon
eclips
object
repres
replic
experi
red
box
part
imag
zoom
display
zstack
b
number
infect
cell
show
coloc
tabul
c
cell
seed
chamber
slide
cell
per
well
cell
untreat
mock
dmso
treat
bortezomib
treat
hour
cell
uninfect
mock
infect
moi
hour
post
infect
cell
fix
process
describ
materi
method
section
cell
probe
ubiquitin
capsid
antibodi
follow
incub
alexafluor
alexafluor
respect
cell
stain
dapi
observ
nuclei
imag
taken
use
nikon
eclips
object
repres
independ
experi
perform
duplic
number
infect
cell
show
coloc
tabul
e
cell
treat
bortezomib
dmso
hour
infect
moi
hour
hour
post
infect
cell
lysat
collect
lyse
quantifi
equal
amount
total
protein
immunoprecipit
capsid
antibodi
resolv
sdspage
subsequ
immunoblot
ubiquitin
top
panel
capsid
bottom
panel
imag
repres
independ
experi
protein
band
quantifi
use
imag
j
softwar
normal
capsid
averag
percent
differ
independ
experi
depict
graphic
up
play
cell
make
attract
target
pathogen
particularli
virus
up
involv
protein
degrad
protein
traffick
transcript
cell
signal
henc
virus
easili
manipul
system
enhanc
replic
recent
mani
virus
demonstr
involv
modifi
up
enhanc
replic
influenza
viru
mous
hepat
viru
studi
aim
investig
effect
function
host
proteasom
system
alphaviru
replic
fda
approv
drug
bortezomib
velcad
use
proteasom
inhibitor
demonstr
broad
spectrum
efficaci
attenu
strain
virul
strain
veev
eeev
weev
nontox
concentr
fig
also
bortezomib
treatment
indic
function
up
earli
stage
viral
life
cycl
necessari
effici
viral
multipl
fig
inhibit
observ
bortezomib
treatment
drug
specif
similar
inhibitori
trend
observ
fig
greater
extent
viral
inhibit
observ
treatment
like
attribut
inhibit
addit
target
certain
lysosom
cystein
proteas
calpain
cathepsin
exampl
studi
schneider
et
al
highlight
inhibit
sarscov
replic
due
mcalpain
inhibitiona
proteasom
independ
mechan
inhibit
could
explain
effect
inhibit
bortezomib
observ
bortezomib
hand
highli
specif
inhibitor
proteasom
addit
target
effect
also
document
revers
one
import
concern
potenti
applic
bortezomib
antivir
therapeut
may
proteasom
play
integr
role
life
cell
inhibit
proteasom
may
deleteri
consequ
host
howev
fact
bortezomibmedi
inhibit
proteasom
revers
process
treatment
regimen
like
restrict
short
time
window
justifi
util
inhibitor
therapeut
addit
inhibit
proteasom
function
inhibit
inflamm
also
achiev
interf
degrad
henc
nuclear
transloc
transcript
activ
import
consequ
neuron
enceph
collect
observ
dove
tail
report
evid
literatur
bortezomib
inhibitor
multipl
virus
includ
nipah
viru
mous
hepat
coronaviru
bortezomib
inhibit
mous
hepat
coronaviru
replic
earli
infecti
process
inhibit
like
due
inhibit
viral
entri
andor
viral
rna
synthesi
compar
studi
bortezomib
treatment
decreas
intracellular
veev
genom
copi
modul
rna
assembl
relev
cytoplasm
structur
fig
import
note
particular
aspect
viral
infecti
cycl
influenc
bortezomib
howev
differ
variou
virus
thu
suggest
differ
viral
famili
may
util
host
up
ubiquitin
mediat
degrad
andor
signal
event
facilit
establish
product
viral
infect
differ
ubiquitin
viral
target
may
also
depend
tropism
natur
host
cell
type
use
experi
horan
et
al
recent
demonstr
capsid
ubiquitin
cytoplasm
infect
macrophag
degrad
proteasom
releas
genom
dna
detect
host
dna
sensor
induc
antivir
respons
valid
confoc
microscopi
fig
immunoprecipit
fig
capsid
ubiquitin
cours
infect
addit
shown
veev
capsid
ubiquitin
earli
infect
fig
may
allow
releas
viral
rna
effici
rna
translat
replic
interestingli
coloc
capsid
ubiquitin
observ
wherea
coloc
capsid
total
ubiquitin
observ
time
point
howev
time
modest
declin
ubiquitin
capsid
record
could
ascrib
possibl
reason
firstli
incom
capsid
may
ubiquitin
could
form
ubiquitin
forth
secondli
sinc
capsid
multifunct
viral
protein
capsid
within
cell
destin
singl
function
time
thirdli
vitro
cell
cultur
system
may
variabl
differ
infect
signal
pattern
may
also
attribut
unsynchron
cell
popul
moreov
capsid
virion
appear
ubiquitin
fig
observ
may
share
similar
nipah
viru
studi
conduct
wang
et
al
up
requir
nuclear
cytoplasm
traffick
matrix
protein
necessari
viral
bud
ongo
studi
laboratori
focus
elucid
type
ubiquitin
occur
capsid
virion
ubiquitin
capsid
protein
requir
viral
egress
conclus
shown
veev
requir
function
up
effici
replic
earli
stage
infect
veev
capsid
ubiquitin
like
requir
function
proteasom
system
degrad
allow
viral
rna
releas
cytoplasm
rna
translat
replic
occur
addit
indepth
studi
puls
chase
experi
use
radiolabel
may
shed
light
actual
stabil
capsid
presenc
proteasom
inhibitor
studi
need
elucid
viral
protein
requir
ubiquitin
ensur
translat
synthesi
veev
rna
investig
ongo
laboratori
futur
work
aid
understand
alphaviru
biolog
viral
manipul
up
system
pave
way
novel
therapeut
strategi
